Congenital muscular dystrophy: Molecular and cellular aspects

Cellular and Molecular Life Sciences

Volumn 62, Issue 7-8, 2005, Pages 809-823

  Jimenez Mallebrera, C ^a   Brown, S C ^a   Sewry, C A ^a,b   Muntoni, F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Robert Jones Agnes Hunt Orthoped H ^*  (United Kingdom)

Author keywords

Collagen VI; Congenital; Dystroglycan; Glycosylation; Integrin; Laminin; Muscular dystrophy; Selenoprotein

Indexed keywords

ALPHA7 INTEGRIN; COLLAGEN TYPE 6; CREATINE KINASE; DYSTROGLYCAN; FUKUTIN; FUKUTIN RELATED PROTEIN; LAMININ ALPHA2; LARGE PROTEIN; PROTEIN; SELENOPROTEIN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENOTYPE; HUMAN; MUSCULAR DYSTROPHY; NEUROMUSCULAR FUNCTION; PATHOLOGY; PHENOTYPE; PRENATAL DIAGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; WALKER WARBURG SYNDROME;

ANTIGENS, CD; DYSTROGLYCANS; HUMANS; INTEGRIN ALPHA CHAINS; LAMININ; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 18544371603     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4510-4     Document Type: Review

References (126)

1. Colognato H. and Yurchenco P. D. (2000) Form and function: the laminin family of heterotrimers. Dev. Dyn. 218: 213-234
2. Yurchenco P. D., Amenta P. S. and Patton B. L. (2004) Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 7: 521-538
3. Sewry C. A, Uziyel Y., Torelli S., Buchanan S., Sorokin L., Cohen J. et al. (1998) Differential labelling of laminin alpha 2 in muscle and neural tissue of dy/dy mice: are there isoforms of the laminin alpha 2 chain? Neuropathol. Appl. Neurobiol. 24: 66-72
4. Patton B. L., Miner J. H., Chiu A. Y. and Sanes J. R. (1997) Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J. Cell Biol. 139: 1507-1521
5. Talts J. F. and Timpl R. (1999) Mutation of a basic sequence in the laminin alpha2 LG3 module leads to a lack of proteolytic processing and has different effects on betal integrin-mediated cell adhesion and alpha-dystroglycan binding. FEBS Lett. 458: 319-323
6. Tome F. M., Evangelista T., Leclerc A., Sunada Y., Manole E., Estournet B. et al. (1994) Congenital muscular dystrophy with merosin deficiency. C.R. Acad. Sci. III 317: 351-357
7. Sewry C. A., Naom I., D'Alessandro M., Ferlini A., Philpot J., Mercuri E. et al. (1996) The protein defect in congenital muscular dystrophy. Biochem. Soc. Trans. 24: 281S
8. Nissinen M., Helbling-Leclerc A., Zhang X., Evangelista T., Topaloglu H., Cruaud C. et al. (1996) Substitution of a conserved cysteine-996 in a cysteine-rich motif of the laminin alpha2-chain in congenital muscular dystrophy with partial deficiency of the protein. Am. J. Hum. Genet. 58: 1177-1184
9. McGowan K. A. and Marinkovich M. P. (2000) Laminins and human disease. Microsc. Res. Tech. 51: 262-279
10. Gullberg D., Tiger C. F. and Velling T. (1999) Laminins during muscle development and in muscular dystrophies. Cell. Mol. Life Sci. 56: 442-460
11. Xu H., Wu X. R., Wewer U. M. and Engvall E. (1994) Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (LAMA2) gene. Nat. Genet. 8: 297-302
12. 2J mice. Hum. Mol. Genet. 6: 1055-1061
13. Miyagoe Y., Hanaoka K., Nonaka I., Hayasaka M., Nabeshima Y, Arahata K. et al. (1997) Laminin α2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett. 415: 33-39
14. Kuang W., Xu H., Vachon P. H., Liu L., Loechel F., Wever U. M. et al. (1998) Merosin-deficient congenital muscular dystrophy: partial genetic correction in two mouse models. J. Clin. Invest. 102: 844-852
15. Minetti C., Bado M., Morreale G., Pedemonte M. and Cordone G. (1996) Disruption of muscle basal lamina in congenital muscular dystrophy with merosin deficiency. Neurology 46: 1354-1358
16. Yurchenco P. D., Cheng Y. S., Campbell K. and Li S. (2004) Loss of basement membrane, receptor and cytoskeletal lattices in a laminin-deficient muscular dystrophy. J. Cell Sci. 117: 735-742
17. Straub V., Rafael J. A., Chamberlain J. S. and Campbell K. P. (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 139: 375-385
18. Muntoni F. and Voit T. (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord. 14: 635-649
19. Sixt M., Engelhardt B., Pausch F., Hallmann R., Wendler O. and Sorokin L. M. (2001) Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol. 153: 933-946
20. Dubowitz D. J., Tyszka J. M., Sewry C. A., Moats R. A., Scadeng M. and Dubowitz V. (2000) High resolution magnetic resonance imaging of the brain in the dy/dy mouse with merosin-deficient congenital muscular dystrophy. Neuromuscul Disord. 10: 292-298
21. Miyagoe-Suzuki Y., Nakagawa M. and Takeda S. (2000) Merosin and congenital muscular dystrophy. Microsc. Res. Tech. 48: 181-191
22. Matsumura K., Yamada H., Saito F., Sunada Y. and Shimizu T. (1997) Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Neuromuscul. Disord. 7: 7-12
23. Guo L. T., Zhang X. U., Kuang W., Xu H., Liu L. A., Vilquin J. T. et al. (2003) Laminin alpha2 deficiency and muscular dystrophy: genotype-phenotype correlation in mutant mice. Neuromuscul. Disord. 13: 207-215
24. Sewry C. A., Naom I., D'Alessandro M., Sorokin L., Bruno S., Wilson L. A. et al. (1997) Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscul. Disord. 7: 169-175
25. Sewry C. A. and Muntoni F. (1999) Inherited disorders of the extracellular matrix. Curr. Opin. Neurol. 12: 519-526
26. Cohn R. D., Herrmann R., Wewer U. M. and Voit T. (1997) Changes of laminin beta 2 chain expression in congenital muscular dystrophy. Neuromuscul. Disord. 7: 373-378
27. Patton B. L., Connoll A. M., Martin P. T., Cunningham J. M., Mehta S., Pestronk A. et al. (1999) Distribution often laminin chains in dystrophic and regenerating muscles. Neuromuscul. Disord. 9: 423-433
28. Vachon P. H., Xu H., Liu L., Loechel F., Hayashi Y., Arahata K. et al. (1997) Disrupted expression in merosin-deficient congenital muscular dystrophy. Clin. Invest. 100: 1870-1981
29. Sewry C. A., Philpot J., Sorokin L. M., Wilson L. A., Naom I., Goodwin F. et al. (1996) Diagnosis of merosin (laminin-2) deficient congenital muscular dystrophy by skin biopsy. Lancet 347: 582-584
30. Korhonen M. and Virtanen I. (2001) Immunohistochemical localization of laminin and fibronectin isoforms in human placental villi. J. Histochem. Cytochem. 49: 313-322
31. Naom I., D'Alessandro M., Sewry C., Ferlini A., Topaloglu H., Helbling-Leclerc A. et al. (1997) The role of immunocytochemistry and linkage analysis in the prenatal diagnosis of merosin-deficient congenital muscular dystrophy. Hum. Genet. 99: 535-540
32. Jimenez-Mallebrera C., Feng L., Brown S. C., Muntoni F. and Sewry C. A. (2003) Do alterations in the laminin beta 2 localisation indicate a role of laminin-4 in congenital muscular dystrophy? Neuromuscul. Disord. 13: 615-668
33. Vilquin J. T., Guerette B., Puymirat J., Yaffe D., Tome F. M., Fardeau M. et al. (1999) Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles. Gene Ther. 6: 792-800
34. Moll J., Barzaghi P., Lin S., Bezakova G., Lochmuller H., Engvall E. et al. (2001) An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413: 302-307
35. Gawlik K., Miyagoe-Suzuki Y., Ekblom P., Takeda S. and Durbeej M. (2004) Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. Hum. Mol. Genet. 13: 1775-1784
36. Ibraghimov-Beskrovnaya O., Milatovich A., Ozcelik T., Yang B., Koepnick K., Francke U. et al. (1993) Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum. Mol. Genet. 2: 1651-1657
37. Holt K. H., Crosbie R. H., Venzke D. P. and Campbell K. P. (2000) Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett. 468: 79-83
38. Winder S. J. (2001) The complexities of dystroglycan. Trends Biochem. Sci. 26: 118-124
39. Chen Y. J., Spence H. J., Cameron J. M., Jess T., Ilsley J. L. and Winder S. J. (2003) Direct interaction of beta-dystroglycan with F-actin. Biochem J. 375: 329-337
40. Russo K., Di Stasio E., Macchia G., Rosa G., Brancaccio A. and Petrucci T. C. (2000) Characterization of the beta-dystroglycan-growth factor receptor 2 (Grb2) interaction. Biochem. Biophys. Res. Commun. 274: 93-98
41. Durbeej M., Larsson E., Ibraghimov-Beskrovnaya O., Roberds S. L., Campbell K. P. and Ekblom P. J. (1995) Non-muscle alpha-dystroglycan is involved in epithelial development. Cell 130: 79-91
42. Williamson R. A., Henry M. D., Daniels K. J., Hrstka R. F., Lee J. C., Sunada Y. et al. (1997) Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice.Hum. Mol. Genet. 6: 831-841
43. Colognato H., Winkelmann D. A. and Yurchenco P. D. (1999) Laminin polymerization induces a receptor-cytoskeleton network. J. Cell. Biol. 145: 619-631
44. Henry M. D., Satz J. S., Brakebusch C., Costell M., Gustafsson E., Fassler R. et al. (2001) Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. J. Cell Sci. 114 1137-1144
45. Cohn R. D., Henry M. D., Michele D. E., Barresi R, Saito F., Moore S. A. et al. (2002) Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110: 639-648
46. Parsons M. J., Campos I., Hirst E. M. and Stemple D. L. (2002) Removal of dystroglycan causes severe muscular dystrophy in zebrafish embryos. Development 129: 3505-3512
47. McDearmon E. L., Combs A. C. and Ervasti J. M. (2001) Differential Vicia villosa agglutinin reactivity identifies three distinct dystroglycan complexes in skeletal muscle. J. Biol. Chem. 276: 35078-35086
48. Endo T. (1999) O-mannosyl glycans in mammals. Biochim. Biophys. Acta 1473: 237-246
49. Kanagawa M., Saito F., Kunz S., Yoshida-Moriguchi T., Barresi R., Kobayashi Y.M. et al. (2004) Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117: 953-964
50. Chiba A., Matsumura K., Yamada H., Inazu T., Shimizu T., Kusunoki S. et al. (1997) Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J. Biol. Chem. 272: 2156-2162
51. Michele D. E., Barresi R., Kanagawa M.. Saito F., Cohn R. D., Satz J. S. et al. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies Nature 418: 417-422
52. Kim D. S., Hayashi Y. K., Matsumoto H., Ogawa M., Noguchi S., Murakami N. et al. (2004) POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG. Neurology 62: 1009-1011
53. Muntoni F., Brockington M., Blake D. J., Torelli S. and Brown S. C. (2002) Defective glycosylation in muscular dystrophy. Lancet 360: 1419-1421
54. Toda T., Segawa M., Nomura Y., Nonaka I., Masuda K., Ishihara T. et al. (1993) Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat. Genet. 5: 283-286
55. Yoshida A., Kobayashi K., Manya H., Taniguchi K., Kano H., Mizuno M. et al. (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1: 717-724
56. Beltran-Valero de Bernabe D., Currier S., Steinbrecher A., Celli J., van Beusekom E., van der Zwaag B. et al. (2002) Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J. Hum. Genet. 71: 1033-1043
57. Brockington M., Blake D. J., Prandini P. Brown S. C., Torelli S., Benson M. A. et al. (2001) Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet. 69: 1198-1209
58. Longman C., Brockington M., Kennedy C., Torelli S., Jimenez-Mallebrera C., Sewry C. et al. (2003) Mutations in the human LARGE gene cause a form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan (MDC1D). Hum. Mol. Genet. 12: 2853-2861
59. Martin-Rendon E. and Blake D. J. (2003) Protein glycosylation in disease: new insights into the congenital muscular dystrophies. Trends Pharmacol. Sci. 24: 178-183
60. Ichimiya T., Manya H., Ohmae Y., Yoshida H., Takahashi K., Ueda R. et al. (2004) The twisted-abdomen phenotype of drosophila POMT1 and POMT2 mutants coincides with their heterophilic protein O-mannosyltransferase activity. J. Biol. Chem. 279: 42638-42647
61. Manya H., Chiba A., Yoshida A., Wang X., Chiba Y., Jigami Y. et al. (2004) Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. USA 101: 500-505
62. Esapa C. T., Benson M. A., Schroder J. E., Martin-Rendon E., Brockington M., Brown S. C. et al. (2002) Functional requirements for fukutin-related protein in the Golgi apparatus. Hum. Mol. Genet. 11: 3319-3331
63. Matsumoto H., Noguchi S., Sugie K., Ogawa M., Murayama K., Hayashi Y. K. et al. (2004) Subcellular localization of fukutin and fukutin-related protein in muscle cells. J. Biochem. (Tokyo) 135: 709-712
64. Jurado L. A., Coloma A. and Cruces J. (1999) Identification of a human homolog of the Drosophila rotated abdomen gene (POMT1) encoding a putative protein O-mannosyltransferase, and assignment to human chromosome 9q34.1. Genomics. 58: 171-180
65. Wilier T., Prados B., Falcon-Perez J. M., Renner-Muller I., Przemeck G. K., Lommel M. et al. (2004) Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc. Natl. Acad. Sci. USA 101: 14126-14131
66. Henion T. R., Qu Q. and Smith F. I. (2003) Expression of dystroglycan, fukutin and POMGnT1 during mouse cerebellar development. Brain Res. Mol. Brain. Res. 112: 177-181
67. Takeda S., Kondo M., Sasaki J., Kurahashi H., Kano H., Arai K. et al. (2003) Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum. Mol. Genet. 2003 12: 1449-1459
68. Grewal P. K. and Hewitt J. E. (2002) Mutation of Large, which encodes a putative glycosyltransferase, in an animal model of muscular dystrophy. Biochim. Biophys. Acta 1573: 216-224
69. Holzfeind P. J., Grewal P. K., Reitsamer H. A., Kechvar J., Lassmann H., Hoeger H. et al. (2002)Skeletal, cardiac and tongue muscle pathology, defective retinal transmission and neuronal migration defects in the Large (myd) mouse defines a natural model for glycosylation-deficient muscle-eye-brain disorders. Hum. Mol. Genet. 11: 2673-2687
70. Saito F., Blank M., Schroder J., Manya H., Shimizu T., Campbell K. P. et al. (2004) Aberrant glycosylation and defective laminin-binding of α-dystroglycan in chicken muscular dystrophy. Neuromuscul. Disord. 14: 561-625
71. Topaloglu H., Brockington M., Yuva Y., Talim B., Haliloglu G., Blake D. et al. (2003) FKRP gene mutations cause congenital muscular dystrophy, mental retardation and cerebellar cysts. Neurology. 25: 988-992
72. Taniguchi K., Kobayashi K., Saito K., Yamanouchi H., Ohnuma A., Hayashi Y. K. et al. (2003) Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum. Mol. Genet. 12: 527-534
73. Beltran-Valero de Bernabe D., Voit T., Longman C., Steinbrecher A., Straub V., Yuva Y. et al. (2004) Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J. Med. Genet. 41: e61
74. Brown S. C., Torelli S., Brockington M., Yuva Y., Jimenez C., Feng L. et al. (2004) Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am. J. Pathol. 164: 727-737
75. Mercuri E., Brockington M., Straub V., Quijano-Roy S., Yuva Y., Herrmann R. et al. (2003) Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann. Neurol. 53: 537-542
76. Herrmann R., Straub V., Blank M., Kutzick C., Franke N., Jacob E. N. et al. (2000) Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy.Hum. Mol. Genet. 9: 2335-2340
77. Moukhles H. and Carbonetto S. (2001) Dystroglycan contributes to the formation of multiple dystrophin-like complexes in brain. J. Neurochem. 78: 824-834
78. Longman C., Mercuri E., Cowan F., Allsop J., Brockington M., Jimenez-Mallebrera C. et al. (2004) Antenatal and post-natal brain magnetic resonance imaging in muscle-eye-brain disease. Arch. Neurol. 61: 1301-1306
79. Jimenez-Mallebrera C., Torelli S., Brown S.C., Feng L., Brockington M., Sewry C. A. et al. (2003) Profound skeletal muscle depletion of α-dystroglycan in Walker-Warburg syndrome. Eur. J. Paed. Neurol. 7: 129-137
80. Sabatelli P., Columbaro M., Mura I., Capanni C., Lattanzi G., Maraldi N. M. et al. (2003) Extracellular matrix and nuclear abnormalities in skeletal muscle of a patient with Walker-Warburg syndrome caused by POMT1 mutation. Biochim. Biophys. Acta 1638: 57-62
81. Wewer U. M., Durkin M. E., Zhang X., Laursen H., Nielsen N. H. and Towfighi J. (1995) Laminin beta 2 chain and adhalin deficiency in the skeletal muscle of Walker-Warburg syndrome (cerebro-ocular dysplasia-muscular dystrophy). Neurology 45: 2099-2101
82. Sunada Y., Saito F., Higuchi I., Matsumura K. and Shimizu T. (2002) Deficiency of a 180-kDa extracellular matrix protein in Fukuyama type congenital muscular dystrophy skeletal muscle. Neuromuscul. Disord. 12: 117-120
83. Ishii H., Hayashi Y. K., Nonaka I. and Arahata K. (1997) Electron microscopic examination of basal lamina in Fukuyama congenital muscular dystrophy. Neuromuscul. Disord. 7: 191-197
84. Herzog C., Has C., Franzke C. W., Echtermeyer F. G., Schlotzer-Schrehardt U., Kroger S. et al. (2004) Dystroglycan in skin and cutaneous cells: beta-subunit is shed from the cell surface. J. Invest. Dermatol. 122: 1372-1380
85. Zhang W., Vajsar J., Cao P., Breningstall G., Diesen C., Dobyns W. et al. (2003) Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available reagents. Clin. Biochem. 36: 339-344
86. Vajsar J., Zhang W., Dobyns W., Biggar D., Hawkins C., Haskins O. A. et al. (2004). Protein O-mannosyl B-1,2-N-acetylglucosaminyltransferase 1 activity is deficient in fibroblasts from patients with muscle-eye-brain disease. Neurom. Disord. 14: 561-625
87. Brockington M., Sewry C. A., Herrmann R., Naom I., Dearlove A., Rhodes M. et al. (2000) Assignment of a form of congenital muscular dystrophy with secondary merosin deficiency to chromosome 1q42. Am. J. Hum. Genet. 66: 428-435
88. Villanova M., Mercuri E., Bertini E., Sabatelli P., Morandi L. and Mora M. (2000) Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome. Neuromuscul Disord 10: 541-547
89. Barresi R., Michele D. E., Kanagawa M., Harper H. A., Dovico S. A., Satz J. S et al. (2004) LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 10: 696-703
90. Burkin D. J. and Kaufman S. J. (1999) The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res. 296: 183-190
91. Martin P. T., Kaufman S. J., Kramer R. H. and Sanes J. R. (1996) Synaptic integrins in developing, adult and mutant muscle: selective association of alpha1, alpha7A and alpha7B integrins with the neuromuscular junction. Dev. Biol. 174: 125-139
92. Velling T., Collo G., Sorokin L., Durbeej M., Zhang H. and Gullberg D. (1996) Distinct alpha 7A beta 1 and alpha 7B beta 1 integrin expression patterns during mouse development: alpha 7A is restricted to skeletal muscle but alpha 7B is expressed in striated muscle, vasculature, and nervous system. Dev. Dyn. 207: 355-371
93. Mayer U., Saher G., Fassler R., Bornemann A., Echtermeyer F., von der Mark H. et al. (1997) Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat. Genet. 17: 318-323
94. Hayashi Y. K., Chou F. L., Engvall E., Ogawa M., Matsuda C., Hirabayashi S. et al. (1998) Mutations in the integrin alpha7 gene cause congenital myopathy. Nat. Genet. 19: 94-97
95. Engvall E. and Wewer U. M. (2003) The new frontier in muscular dystrophy research: booster genes. FASEB J. 17: 1579-1584
96. Bruns R. R., Press W., Engvall E., Timpl R. and Gross J. (1986) Type VI collagen in extracellular, 100-nm periodic filaments and fibrils: identification by immunoelectron microscopy. J. Cell Biol. 103: 393-404
97. Camacho Vanegas O., Bertini E., Zhang R. Z., Petrini S., Minosse C. and Sabatelli P. (2001) Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc. Natl. Acad. Sci. USA 98: 7516-7521
98. Demir E., Sabatelli P., Allamand V., Ferreiro A., Moghadaszadeh B., Makrelouf M. et al. (2002) Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am. J. Hum. Genet. 70: 1446-1458
99. Pan T. C., Zhang R. Z., Sudano D. G., Marie S. K., Bonnemann C. G. and Chu M. L. (2003) New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am. J. Hum. Genet. 73: 355-369
100. Bonaldo P., Braghetta P., Zanetti M., Piccolo S., Volpin D. and Bressan G. M. (1998) Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum. Mol. Genet. 7: 2135-2140
101. Vitale P., Braghetta P., Volpin D., Bonaldo P. and Bressan G. M. (2001) Mechanisms of transcriptional activation of the coloal gene during Schwann cell differentiation. Mech. Dev. 102: 145-156
102. Kuo H. J., Maslen C. L., Keene D. R. and Glanville R. W. (1997) Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J. Biol. Chem. 272: 26522-26529
103. Tillet E., Wiedemann H., Golbik R., Pan T. C., Zhang R. Z. Mann K. et al. (1994) Recombinant expression and structural and binding properties of alpha 1(VI) and alpha 2(VI) chains of human collagen type VI. Eur. J. Biochem. 221: 177-185
104. Bidanset D. J., Guidry C., Rosenberg L. C., Choi H. U., Timpl R. and Hook M. (1992) Binding of the proteoglycan decorin to collagen type VI. J. Biol. Chem. 267: 5250-5256
105. Wiberg C., Klatt A. R., Wagener R., Paulsson M., Bateman J. F., Heinegard D. et al. (2003) Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. J. Biol. Chem 278: 37698-37704
106. Tillet E., Gential B., Garrone R. and Stallcup W. B. (2002) NG2 proteoglycan mediates B1 integrin-independent cell adhesion and spreading on collagen VI. J. Cell. Biochem. 86: 726-736
107. Atkinson J. C., Ruhl M., Becker J., Ackermann R. and Schuppan D. (1996) Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro. Exp. Cell. Res. 228: 283-291
108. Ruhl M., Sahin E., Johansen M., Somasundaram R., Manski D., Riecken E. O. et al. (1999) Soluble collagen Vi drives senun-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J. Biol. Chem. 274: 34361-34368
109. Bonaldo P., Russo V., Bucciotti F., Doliana R. and Colombatti A. (1990) Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues. Biochemistry 29: 1245-1254
110. Ishikawa H., Sugie K., Murayama K., Ito M., Minami N., Nishino I. et al. (2002) Ullrich disease: collagen VI deficiency: EM suggests a new basis for muscular weakness. Neurology 24 (6): 920-923
111. Niiyama T., Higuchi I., Suehara M., Hasf T., Shiraishi T., Nakagawa M. et al. (2002) Electron microscopic abnormalities of skeletal muscle in patients with collagen VI deficiency in Ullrich's disease. Acta Neuropathol. 104: 67-71
112. Sabatelli P., Bonaldo P., Lattanzi G., Braghetta P., Bergamin N., Capanni C. et al. (2001) Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol. 20: 475-486
113. Irwin W. A., Bergamin N., Sabatelli P., Reggiani C., Megighian A., Merhnin E. et al. (2003) Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 35: 367-371
114. Demir E., Ferreiro A., Sabatelli P., Allamand V., Makri S., Echenne B. et al. (2004) Collagen VI status and clinical Severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families linked to the COL6 loci. Neuropediatrics 35: 103-112
115. Mercuri E., Yuva Y., Brown S. C., Brockington M., Kinali M., Jungbluth H. et al. (2002) Collagen VI involvement in Ullrich syndrome: a clinical, genetic and immunohistochemical study. Neurology 58: 135
116. Ishikawa H., Sugie K., Murayama K., Awaya A., Suzuki Y., Noguchi S. et al. (2004) Ullrich disease due to deficiency of collagen VI in the sarcolemma. Neurology 62: 620-623
117. Jimenez-Mallebrera C., Maioli M., Feng L., Brown S., Lampe A. K., Bushby K. et al. (2004) Normal collagen VI immunolabelling in Ullrich's congenital muscular dystrophy with COL6 mutations. Neuromusc. Disord. 14: 561-625
118. Higuchi I., Shiraishi T., Hashiguchi T., Suehara M., Niiyama T., Nakagawa M. et al. (2001) Frameshift mutation in the collagen VI gene causes Ullrich's disease. Ann. Neurol. 50: 261-265
119. Hu J., Higuchi I., Shiraishi T., Suehara M., Niiyama T., Horikiri T. et al. (2002) Fibronectin receptor reduction in skin and fibroblasts of patients with Ullrich's disease. Muscle Nerve 26: 696-701
120. Brockington M., Brown S. C., Lampe A., Yuva Y., Feng L., Jimenez-Mallebrera C. et al. (2004) Prenatal diagnosis of Ullrich congenital muscular dystrophy using haplotype analysis and collagen VI immunocytochemistry. Prenat. Diagn. 24: 440-444
121. Moghadaszadeh B., Petit N., Jaillard C., Brockington M., Roy S.Q., Merlini L. et al. (2001) Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat. Genet. 29: 17-18
122. Petit N., Lescure A., Rederstorff M., Krol A., Moghadaszadeh B., Wewer U. M. et al. (2003) Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern. Hum. Mol. Genet. 12: 1045-1053
123. Ferreiro A., Quijano-Roy S., Pichereau C., Moghadaszadeh B., Goemans N., Bonnemann C. et al. (2002) Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am. J. Hum. Genet. 71: 739-749
124. Ferreiro A., Ceuterick-de Groote C., Marks J. J., Goemans N., Schreiber G., Hanefeld F. et al. (2004) Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Ann. Neurol. 55: 676-686
125. Jungbluth H., Sewry C., Brown S. C., Manzur A. Y., Mercuri E., Bushby K. et al. (2000) Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromusc. Disord. 10: 264-273
126. Voit T., Parano E., Straub V., Schroder J. M., Schaper J., Pavone P. et al. (2002) Congenital muscular dystrophy with adducted thumbs, ptosis, external ophthalmoplegia, mental retardation and cerebellar hypoplasia: a novel form of CMD. Neuromuscul. Disord. 12: 623-630